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Abstract
cAMP and cGMP are well established second messengers that are essential for numerous
(patho)physiological processes. These purine cyclic nucleotides activate cAK and cGK, re-
spectively. Recently, the existence of cCMP was described, and a possible function for this
cyclic nucleotide was investigated. It was postulated that cCMP plays a role as a second
messenger. However, the functions regulated by cCMP are mostly unknown. To elucidate
probable functions, cCMP-binding and -activated proteins were identified using different
methods. We investigated the effect of cCMP on purified cyclic nucleotide-dependent pro-
tein kinases and lung and jejunum tissues of wild type (WT), cGKI-knockout (cGKI KO) and
cGKII-knockout (cGKII KO) mice. The catalytic activity of protein kinases was measured by
a (γ-32P) ATP kinase assay. Cyclic nucleotide-dependent protein kinases (cAK, cGKI and
cGKII) in WT tissue lysates were stimulated by cCMP. In contrast, there was no stimulation
of phosphorylation in KO tissue lysates. Competitive binding assays identified cAK, cGKI,
and cGKII as cCMP-binding proteins. An interaction between cCMP/MAPK and a protein-
protein complex of MAPK/cGK were detected via cCMP affinity chromatography and co-
immunoprecipitation, respectively. These complexes were abolished or reduced in jejunum
tissues from cGKI KO or cGKII KO mice. In contrast, these complexes were observed in the
lung tissues fromWT, cGKI KO and cGKII KO mice. Moreover, cCMP was also able to stim-
ulate the phosphorylation of MAPK. These results suggest that MAPK signaling is regulated
by cGMP-dependent protein kinases upon activation by cCMP. Based on these results, we
propose that additional cCMP-dependent protein kinases that are capable of modulating
MAPK signaling could exist. Hence, cCMP could potentially act as a second messenger in
the cAK/cGK and MAPK signaling pathways and play an important role in physiological pro-
cesses of the jejunum and lung.
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Introduction
The principle of cyclic nucleotides as intracellular signaling molecules is well established in re-
gard to the purinergic cyclic nucleotides cyclic adenosine monophosphate (cAMP) and cyclic
guanosine monophosphate (cGMP). However, more recent data has suggested that the pyrimi-
dinic cyclic nucleotides cyclic cytidine monophosphate (cCMP) and cyclic uridine monophos-
phate (cUMP) might also exert an intracellular function. These cyclic nucleotides can be
synthesized in eukaryotic cells by soluble nucleotidyl cyclases, such as soluble guanylyl cyclase
(sGC) or soluble adenylyl cyclase (sAC) [1,2]. Furthermore, the synthesis of pyrimidinic cyclic
nucleotides has been detected in bacterial cells (e.g., Pseudomonas aeruginosa) and was shown
to be stimulated by bacterial toxins (e.g., edema factor) [3–5]. These observations raise the
question of whether possible target proteins and/or effector systems of these cyclic nucleotides
exist. Therefore, studies have sought to elucidate a possible role for these cyclic nucleotides as
intracellular second messengers [6]. cCMP activates purified cGMP-dependent protein kinase
I (cGKI) isoforms cGKIα and cGKIβ, cGMP-dependent protein kinase II (cGKII) and cAMP-
dependent protein kinase (cAK) [7,8]. Additionally, exogenous application of cCMP induced
cGK-mediated modulation of vascular relaxation, and the inhibition of platelet aggregation via
cGMP-kinase I was detected using transgenic mice [7]. The binding of cCMP to cAKRIα (a
regulatory subunit of cAK) was observed in mammalian cells [9]. However, to date it is not
known whether cCMP can function as an intracellular messenger molecule in vivo. A critical
point is whether the concentration of cCMP in vivo is sufficient to activate the identified signal-
ing proteins. Moreover, a selective signaling pathway for cCMP has not yet been demonstrated.
Although cCMP could act via pathways that are usually activated by other cyclic nucleotides
such as cAMP/cGMP, further downstream effectors may exist. Moreover, the stimuli inducing
cCMP synthesis could differ from those of the other cyclic nucleotide systems, and therefore a
specific role for cCMP could be elucidated. Hence, the discovery of further cCMP targets is im-
portant for the identification of probable cCMP functions. To elucidate possible targets of
cCMP in tissues, we performed cCMP kinase activity assays and cCMP-affinity chromatogra-
phy of lung or intestinal murine tissues and analyzed the relevant proteins using mass spec-
trometry and immunoblotting analysis. These tissues were selected because cGKI and/or
cGKII are present in high concentrations. cGKI was originally purified from lung (which con-
tains high amounts of cGKI) [10,11], intestinal tissues including jejunum contain high concen-
trations of cGKI and cGKII [11,12]. We confirmed that cGKI and cAK are cCMP-interacting
proteins, and identified cGKII and MAPK as possible cCMP signaling molecules.
Materials and Methods
Materials
All cyclic nucleotides (3',5'-cCMP (cCMP); N4, 2'- O- Dibutyrylcytidine- 3', 5'- cyclic mono-
phosphate (DB-cCMP); 3’,5’-cAMP (cAMP); 3’,5’-cGMP (cGMP)), the cCMP or cGMP cou-
pled agarose beads and the corresponding EtOH-NH-agarose were provided by the BIOLOG
Life Science Institute (Bremen, Germany). The different primary antibodies were purchased as
indicated in the different sections. PhosStop tablets were ordered from Roche Diagnostics
(Basel, Switzerland). The ProteoSilver Silver Stain Kit and all the other chemicals were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA).
Animals
129/Sv- cGKII-knockout (cGKII KO) and 129/Sv- wild type (WT) mice of both genders were
used at an age>8 weeks. 129/Sv- cGKI-knockout (cGKI KO) mice were used at an age of 4–6
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weeks due to the low survival rate of the adult animals. We kindly thank Prof. Franz Hofmann
for providing breeding pairs of the cGKI and cGKII KO mice. All mice were bred and main-
tained in the animal facilities of the University of Regensburg. Surgery was performed under
anesthesia (2% isofluran). All experiments conformed to the guidelines for the care and use of
laboratory animals published by the US National Institute of Health and were approved by the
local governmental committee.
Tissue lysate preparation
After anesthetizing and perfusing the mice through the abdominal aorta with 0.9% NaCl-
solution containing 10 IU/mL heparin, the organs were removed and cleaned. The tissues
were immediately frozen in liquid nitrogen and stored at -80°C before use. The homogeniza-
tion was performed with a tissue homogenizer (Ultraturrax, Janke&Kunkel KG, IKA-Wert,
Staufen i. Br., Germany) in extraction buffer (20 mM Tris-HCl, 250 mM NaCl, and 2%
Lubrol [v/v] [nonaethyleneglykol nonadodecylether], pH 8.0) containing protease inhibitors
(1 μM leupeptin, 300 μM PMSF, and 1 mM benzamidine). Additionally, a phosphatase in-
hibitor cocktail (PhosStop) was added in the phosphorylation experiments to conserve the
phosphorylation state of the proteins. The homogenates were centrifuged (10 min, 4°C,
13,000xg), and the supernatant fractions were separated for further experiments and the de-
termination of the protein concentrations using the Qubit system (Life Technologies, Darm-
stadt, Germany).
Measurement of kinase activity
The catalytic activity of protein kinases, which was dependent on the concentration of cyclic
nucleotides, was measured using a (γ-32P) ATP kinase assay. Recombinant protein kinases
cGKI (both isoforms, bovine) and cGKII (mouse) were purified in our lab following expres-
sion in SF9 cells as described previously [13–15]. Purified protein kinase cAK was purchased
from Sigma-Aldrich. The tissue lysates were prepared as described above except that a differ-
ent extraction buffer was used (20 mM Tris-HCl, 100 mM NaCl, pH 8.0, and protease inhibi-
tors). The reaction was started by adding 20 μL of the protein sample to the reaction mixture
(50 mMMES, pH 6.9, 0.4 mM EGTA, 1 mMMg-acetate, 10 mM NaCl, 0.1% (w/v) BSA, 10
mM DTT, 40 μM substrate peptide IRAGtide (Sequence: RRRVSVAV) or VASPtide (Se-
quence: RRKVSKQE), 2 μM cAK-inhibitor peptide, 0.1 mM [γ-32P] ATP (100 cpm/pmol)
and ± cNMP at increasing concentrations). The Ka values for the different cyclic nucleotides
were determined with GraphPad Prism based on the results of three to four experiments,
using increasing concentrations of cNMP (1 nM to 50 mM). Ka values in experiments with tis-
sue lysates were determined in the same way as in the experiments with purified enzyme, but
only two representative concentrations were shown. To eliminate cAK-phosphorylation, a
cAK-inhibitor peptide (AS5-24) was applied in all assays with tissues. This substance is a po-
tent, synthetic peptide inhibitor of cAMP-dependent protein kinase with a Ki value of 2.3 nM
[16], but is also a weak inhibitor of cGMP-dependent protein kinase. However, the conditions
were selected using a concentration of AS5-24 were cAK is completely inactivated and cGK is
inhibited to a minimal amount [17]. After incubation (5 min at 30°C), the samples were trans-
ferred to Whatman P-81 filter papers (Sigma-Aldrich) and the reaction was stopped by the
addition of 75 mM H3PO4. Rotiscint scintillation liquid (Carl Roth GmbH & Co. KG, Karls-
ruhe, Germany) was added to the dried phosphocellulose papers to measure the counts per
minute using a β-counter (Tri Carb 2800TR Liquid Scintillation Analyzer, Perkin Elmer, Rod-
gau, Germany).
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Competition binding assay
cCMP-binding proteins were identified using competitive binding assays modified for the anal-
ysis of tissues from [9]. Tissue lysates were mixed with additional extraction buffer (see above)
and centrifuged (15 min, 4°C, 24,000xg) to separate non-lysed proteins and cell fractions.
Then, we added N4-(6-aminohexyl)-cCMP agarose (4-AH-cCMP) beads (ligand density ~
6 μmol / mL of settled gel) and corresponding control agarose (EtOH-NH, Ctrl.) beads. The
mixtures were blocked with 3% BSA and washed three times with extraction buffer. Clarified
protein lysate (700 μg), 100 μM isobutyl-methylxanthine and 1 mM DTT were added to the
beads. Next, 200 μM, 2 mM cCMP or 2 mM cAMP was added (indicated with + cNMP) or
omitted (indicated with—cNMP). For some experiments 8-(2-aminoethylthio)-3’,5’-cGMP
agarose (ligand density ~6.5 μmol/mL of settled gel)was used and for competition 200 μM
cGMP was added. Untreated tissue lysate (1 μg/μL, indicated with input) and purified enzyme
(1.5 ng/μL) were used as the controls. After the incubation (4°C, overnight), the samples were
centrifuged (3 min, 4°C, 20,000xg) and the sedimented beads were washed another three times.
Afterwards, the washing solution was completely removed and the proteins were eluted with
Laemmli buffer. The bound proteins were analyzed by silver staining and immunoblotting.
Co-immunoprecipitation
Co-immunoprecipitation was used to detect cCMP-dependent protein complexes. Protein
A-Sepharose beads (Sigma-Aldrich, antibody-binding capacity 6 mg per mL) were blocked
with 3% BSA, washed three times with extraction buffer (see above) and incubated with a spe-
cific primary MAPK antibody (p44/42 MAPK, Cell Signaling Technology, Leiden, The Nether-
lands) at 4°C for 4 hours. Then, the beads were washed again and the clarified protein lysate
(700 μg per IP experiment) was added prior to incubation (+ 1 mMDTT, 4°C, overnight). The
subsequent steps were identical to those described above (competition binding assay).
Phosphorylation analysis
Tissue lysates (50 μg) were added to buffer (50 mMMES, 10 mM ATP, pH 7.2, protease and
phosphatase inhibitors) for the phosphorylation studies and treated with DB-cCMP, (100 μM,
BIOLOG) for the indicated timepoints (15/30/60 min, 37°C). As a control, unstimulated tissue
lysate (50 μg, indicated with `us`) was used. Control samples (us) were treated the same as the
cyclic nucleotide stimulated samples except that water was added instead of DB-cCMP. Data
were expressed as x-fold MAPK phosphorylation relative to the untreated control samples.
Quantification of MAPK phosphorylation was always in comparison to total MAPK and the
unstimulated sample. To analyze the role of cAK in MAPK phosphorylation, a cAK-inhibitor
peptide (AS5-24, 10 μM) was added or omitted. AS5-24 was only added in lung or jejunumWT
samples, in every single sample (‘us’, 15, 30, 60) together with the buffer without preincubation
(indicated with + AS5-24). The phosphorylation state of the stimulated and unstimulated pro-
tein samples (each 2.5 μg/μL) was detected by SDS-PAGE and Western blotting.
SDS-PAGE andWestern blotting
The samples were pretreated as described in the sections above. Proteins were separated by
11.5% sodium-dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; equal volumes
(15 μL, concentration as indicated in figure legends) of protein were loaded in every lane) and
transferred to a PVDF membrane using a semi-dry transfer system (also described in [18]). For
one hour, the blotted membrane was blocked with 5% nonfat milk in TBST (10 mM Tris-HCl,
150 mMNaCl, pH 8.0, with 0.1% Tween 20), and then washed with TBST. For protein
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detection, the blot was incubated with a primary antibody (4°C, overnight) and then with a cor-
responding goat anti-rabbit IgG secondary antibody coupled to horseradish peroxidase (dilu-
tion 1:50,000, room temperature, 2 hours) (Dianova GmbH, Hamburg, Germany). The rabbit
primary antibodies used were: rabbit anti-cGKIcommon (polyclonal, dilution 1:200, detection
of both isoforms), rabbit anti-cGKIα (polyclonal, dilution 1:500) [11], rabbit anti-cGKII (poly-
clonal antibody, dilution 1:1000) [19], rabbit anti-cAKRIα/β (1:500, polyclonal) (Santa Cruz
Biotechnology, Heidelberg, Germany), polyclonal rabbit anti-p44/42 MAPK and monoclonal
rabbit anti-p-p44/42 MAPK (dilution 1:1000 for both) (Cell Signaling Technology). As control
untreated jejunum or lung tissue lysate (1 μg/μL, indicated with input) was used. In some cases,
the membranes had to be stripped for further detection; after washing three times with TBST, a
stripping solution (100 mMNaOH, 2% SDS, 0.5% DTT, 37°C, 30 min) was used. Then, retreat-
ment with another antibody was possible. The proteins were visualized with Clarity Western
ECL substrate using the ChemiDoc MP system (both Bio-Rad Laboratories GmbH). The quan-
tification was performed with ImageLab Software (Bio-Rad Laboratories GmbH).
Silver staining and mass spectrometric identification
In addition to SDS-PAGE andWestern blotting, cCMP-binding proteins were visualized by sil-
ver staining using the ProteoSilver Plus Silver Stain Kit (Sigma-Aldrich) as described in the
manufacturer’s instructions. Bands of interest were excised and washed according to the proto-
col of Shevchenko et al. [20]. Briefly, gel bands were washed twice in an alternating fashion
with 50 μL 50 mMNH4HCO3 (washing buffer A) and 25 mMNH4HCO3 in 50% acetonitrile
(washing buffer B). The reduction of disulfide bridges was accomplished by incubation in 10
mMDTT in washing buffer A at 56°C for 30 min. Cysteines were carbamidomethylated by in-
cubation with 5 mM iodoacetamide in washing buffer A for 30 min. Subsequently, the washing
steps were repeated, and the gel pieces were dried in a vacuum centrifuge. They were rehy-
drated using 6 μL of trypsin solution (10 ng/μL in washing buffer A) and incubated overnight
at 37°C for in-gel digestion. The resulting peptides were eluted with 20 μL of 5% formic acid
and subjected to nano-LC-MS/MS-analysis on an Ultimate 3000 nano-HPLC-system (Dionex
GmbH, Idstein, Germany) using a 1 h binary gradient directly coupled to a QTOF mass spec-
trometer (QStar XL, Applied Biosystems, Darmstadt, Germany) as previously described [21].
The tandem-MS spectra were aligned with the Uniprot-database using the Protein Pilot 4.5
software (ABSciex, Darmstadt, Germany) applying the two-peptide rule.
Statistical Analysis
All data are expressed as the mean ± SEM. Error bars in the Figures indicate SEM. The t-test
was used to calculate significant differences between two means; the ANOVA test was used to
assess differences between three or more means. P-values are indicated as follows:  p<0.05,
 p<0.01, p<0.001; n.s. not statistically significant (p>0.5); n describes the number
of experiments.
Results
Activation of cyclic nucleotide dependent kinases by cCMP in vitro and
in tissues
In previous studies, we showed that cCMP is able to stimulate purified cAMP- and cGMP-
dependent kinases cAK and cGKI [7,8]. Based on these results, we used VASPtide
(RRKVSKQE) as a well-established peptide substrate for the determination of cGKI and cAK
stimulation. To confirm that cCMP activates kinases and to investigate whether this activation
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is dependent on the substrate used, we performed (γ-32P) ATP kinase assays using purified
protein kinases and a novel substrate peptide called IRAGtide (RRRVSVAV) that contains ser-
ine 696 as the identified cGKI phosphorylation site of IRAG [22]. Fig 1 demonstrates that both
cGKI isoforms (Fig 1A) and cAK (Fig 1B, Ka(cCMP): 71±11 μM) could be activated by cCMP
in a concentration dependent manner. The Ka(cCMP) for cGKIα and cGKIβ were 26±6 μM
and 70±5 μM, respectively. Furthermore, cCMP stimulated the activation of cGKII [Ka(cCMP):
110±8 μM]. Therefore, both VASPtide and IRAGtide are suitable peptide substrates for the ki-
nase assays. Interestingly, the measured kinase activation differed slightly between the substrate
peptides. This result suggests that substrate specificity for these kinases is mediated by peptide
sequences not integrated into the phosphorylated consensus sequence.
The next step was to examine whether cCMP could stimulate endogenous cGKs in jejunum
and lung tissue lysates. Both tissue types are known to contain cGKs in high concentrations
[10–12]. Wild-type (WT) and cGKI-knockout (KO) tissue lysates were prepared, and kinase
assays were performed as described above. A cAK-inhibitor peptide (AS5-24) was added to
eliminate cAK phosphorylation. Treatment of WT tissue lysates with cCMP (100 μM) resulted
in a 2- to 2.5-fold stimulation compared with water alone (ctrl) (Fig 2). Comparable results
Fig 1. Activation of cGKIα, cGKIβ and cAK by cCMP (A) In vitro concentration response curves of
purified, recombinant bovine cGKI isozymes andmurine cGKII with cCMP as an activator and
IRAGtide (RRRVSVAV) as a substrate (B) In vitro concentration response curves of purified,
recombinant bovine cAKwith cCMP and IRAGtide. Error bars indicate mean ± SEM of three
independent experiments.
doi:10.1371/journal.pone.0126057.g001
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were achieved using VASPtide and IRAGtide as the substrate peptides. Interestingly this stimu-
lation of phosphorylation was not detectable in cGKI KO tissue lysates, indicating that cCMP-
dependent phosphorylation occurs via cGKI in jejunum and lung tissues. To relate these cCMP
mediated effects to cAMP and cGMP we performed (γ-32P) ATP kinase assays using increasing
cAMP or cGMP concentrations (1 nM-50 mM). S1 Fig shows the activation of kinases at vari-
ous cNMP concentrations in WT and cGKI KO tissues (lung or jejunum) using the two differ-
ent substrate peptides. Interestingly the cGMP mediated stimulation of kinases in WT tissue is
Fig 2. Activation of kinases in tissues of wild type (WT) and cGKI-knockout (KO) mice using two
different substrate peptides: VASPtide (RRKVSKQE) and IRAGtide (RRRVSVAV) (A) Stimulation of
endogenous cGKs in jejunum tissue lysates after activation with water alone (ctrl) or cCMP (5 or
100 μM) (B) Same panel as (A) using lung tissue lysates.Data were expressed as x-fold stimulation
relative to control samples (water alone). Error bars indicate mean ± SEM of four independent experiments.
Asterisks indicate statistically significant differences, ns: not statistically significant.
doi:10.1371/journal.pone.0126057.g002
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almost comparable to the cCMP mediated effect, resulting in a 1.8 to 2.8fold stimulation of en-
dogenous kinases (S1A/S1B Fig). The effect of cGMP in WT tissue lysates was completely abol-
ished in cGKI KO tissue lysates as previously observed with cCMP. cAMP enhanced
phosphorylation of kinases in WT lung tissue lysate but not in jejunumWT or cGKI KO tissue
(S1C/S1D Fig). As a cAK inhibitor peptide (AS5-24) was added to eliminate cAK phosphoryla-
tion, a crossreaction with other kinases is possible. In these experiments the kinases in jejunum
WT tissue possessed a ~70fold lower Ka value (2±0.5 μM) for cGMP (S1B Fig) than for cCMP
(140±35 μM) (Fig 2A), using IRAGtide as peptide substrate. This fact suggests that higher con-
centrations of cCMP (relative to cGMP) may be required in vivo to activate endogenous ki-
nases. The affinity of cCMP for cGKs is much lower than that of cGMP.
Identification of cCMP-binding proteins
To illuminate the exact role of cCMP, we sought to identify proteins that interact with this cy-
clic nucleotide. Therefore, lung and jejunumWT tissue lysates were analyzed by cCMP-affini-
ty chromatography and gel electrophoresis of the bound proteins, followed by silver staining
(Fig 3, S1 Table) or Western blotting (Fig 4A/4B, S2A/S2B Fig). cCMP was added (+) or omit-
ted (-) during the affinity chromatography experiments to investigate the specificity of the
binding. The concentration of 200 μM (Fig 4) or 2 mM cCMP (Fig 3, S2 Fig) was equally used.
Fig 3. Identification of cCMP-binding proteins. Analysis of lung tissue lysates of wild type mice by
immunoprecipitation (using 4-AH-cCMP agarose or EtOH-NH agarose as a control), gel electrophoresis and
silver staining. Proteins were detected by mass spectrometric analysis (see S1 Table). cGKI is designated
with 1, serum albumin with 2 and 4, HSP7C and 5’-nucleotidase with 3, cAKIIα/Iα reg with 5/6, actin and 60S
ribosomal protein L4 with 7.
doi:10.1371/journal.pone.0126057.g003
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Using mass spectrometry of silver-stained gel bands, the cGKIα (76 kDa) and cAKIIα (50
kDa)/Iα (47 kDa) reg (regulatory subunits) were identified as cCMP-binding proteins (Fig 3,
S1 Table). This binding was verified using Western blotting analysis with the specific primary
antibodies cGKIcommon, cGKII and cAKRIα/β, using a more physiological cCMP concentra-
tion (200 μM). Fig 4A shows the corresponding immunoblots obtained using lung WT tissue
lysate. Interactions between cGKI/cCMP and cGKII/cCMP were also detected in jejunum tis-
sue (Fig 4B). Specific binding of cCMP to cAKRIα/β was also detected. As previously reported
[9], we also performed this experiment with 2 mM cCMP (S2A/S2BFig); the effect was the
same except that the signals were stronger than with 200 μM cCMP. Furthermore we checked
if other cyclic nucleotides, such as cAMP (2 mM) overcome the interaction between cCMP
and kinases, such as cGKI, but there was no specific interaction (S2C Fig).Hence, cCMP inter-
acts with both cGK and cAK in the analyzed tissues. Comparable results were obtained using
jejunumWT tissue lysate.
Interaction of MAPK with cGK
While searching for other cCMP-interacting proteins, we found several publications that pos-
tulated a possible role for cyclic nucleotides and protein kinases interacting with the MAPK
Fig 4. Identification of cCMP-binding proteins (A) Lung tissue lysate (WT) was incubated with 4-AH-
cCMP agarose beads or EtOH-NH-agarose beads (ctrl). For the competition experiments, cCMP (200 μM)
was added (+) or omitted (-) as described in the Material and Methods. cCMP-binding proteins were analyzed
by electrophoresis and immunoblotting with antibodies directed against cGKIc, cGKII, cAKRIα/β or MAPK.
Untreated tissue lysate (1 μg/μL, indicated with input) and purified enzyme (1.5 ng/μL) were used as the
controls. Purified enzymes are designated with * (B) Same panel as (A) using jejunum (WT) lysate. (S2 Fig)
Same experiment depicted in Fig 4 using +/- 2 mM cCMP for competition (WT tissue lysates).
doi:10.1371/journal.pone.0126057.g004
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(mitogen-activated protein kinase) signaling pathway [23–25]. Therefore, we analyzed whether
cCMP interfered with MAPK signaling and detected an interaction between cCMP and p44/42
MAPK. The binding was specific in jejunum (Fig 4B) and lung (Fig 4A) WT tissues, because
the addition of an excess of cyclic nucleotide (200 μM cCMP) resulted in the loss of the associa-
tion of MAPK with the cCMP affinity matrix. Particularly, the p42 MAPK isoform was precipi-
tated in experiments using 200 μM cCMP (Fig 4) or 2 mM cCMP (S2 Fig). To determine
whether cGK was essential for this interaction, we performed several competition experiments
using tissues from KOmice. MAPK was precipitated from lung cGKI KO and cGKII KO tis-
sues in the same manner as WT tissue (Fig 5A). In contrast, specific binding was only observed
Fig 5. Identification of cCMP-binding proteins (A) Lung tissue lysate (cGKI KO or cGKII KO) was
incubated with 4-AH-cCMP agarose beads or EtOH-NH-agarose beads (ctrl). For the competition
experiments, cCMP (200 μM) was added (+) or omitted (-) as described in the Material and Methods.
Untreated tissue lysate (1 μg/μL, indicated with input) was used as an additional control. cCMP-binding
proteins were analyzed by electrophoresis and immunoblotting with an antibody directed against p44/42
MAPK. (B) Same panel as (A) using jejunum tissue lysate. (S3 Fig) Same experiment depicted in Fig 5 using
+/- 2 mM cCMP for competition (WT, cGKI KO and cGKII KO tissue lysates).
doi:10.1371/journal.pone.0126057.g005
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using cGKII KO samples in the jejunum tissues (Fig 5B). Working with 2 mM cCMP the same
result was achieved (S3 Fig). Interestingly, MAPK was not precipitated from the jejunum cGKI
KO tissue lysate (Fig 5B, S3B Fig).
Next, we performed a co-immunoprecipitation to detect a possible protein-protein interac-
tion between cGK and MAPK (Fig 6). MAPK was precipitated using the cGKIα and cGKII an-
tibodies, indicating an interaction between MAPK, cGK and the cyclic nucleotides. We also
performed precipitation studies using 8-AET-cGMP agarose and 200 μM cGMP was added
(indicated with +) or omitted (indicated with-). Interestingly, no specific interaction of MAPK
with cGMP agarose was detected, both in lung and jejunumWT tissue (S4 Fig).
Next, we analyzed whether tissue phosphorylation of MAPK was influenced by the addition
of the cyclic nucleotide cCMP, and found that the phosphorylation of MAPK was stimulated
when 100 μMDB-cCMP was added to the WT tissue lysate for 15–60 min. As a control, an
unstimulated tissue lysate was analyzed and compared with the stimulated samples. The con-
trol samples (us) were treated identically to the DB-cCMP stimulated samples except that
water was added instead of DB-cCMP water. Treatment of lung WT tissue lysate (S5 Fig) with
DB-cCMP for 15 min resulted in ~2.5-fold stimulation of p42 MAPK phosphorylation com-
pared to the control, while treatment for 60 min resulted in ~6-fold stimulation. p44 MAPK
phosphorylation was less pronounced, but remained significant; the phosphorylation was in-
creased ~2-fold after 15 min of stimulation and ~4-fold after 1 h. The same trend was observed
in jejunumWT tissue lysate (Fig 7), with ~13.5-fold stimulation of p42 MAPK phosphoryla-
tion after 15 min of stimulation and ~2.5-fold stimulation of p44 MAPK phosphorylation in
the same time frame. After stimulation for 60 min, the p44 MAPK phosphorylation level in-
creased to ~8-fold, while the p42 MAPK phosphorylation level stayed the same. In comparison
to lung tissue, phosphorylation of MAPK in jejunum tissue was significantly stronger (S6 Fig).
In both lung and jejunum tissue, MAPK phosphorylation could be stimulated by cCMP. Inter-
estingly, the phosphorylation of MAPK was inhibited by the addition of the PKA inhibitor
AS5-24, suggesting a stimulatory function for PKA in cCMP-mediated MAPK phosphorylation.
There is a need for further studies analyzing MAPK activation by other cyclic nucleotides. To
elucidate the role of cGK in lung and jejunum tissues in this process, we used cGKII knockout
(cGKII KO) and cGKI knockout (cGKI KO) mice. The experiment was conducted as described
above (the same experiment using WT tissue). We detected phosphorylation both in the jeju-
num and lung tissues from cGKI KO and cGKII KO mice (Fig 8, S7 Fig). It is interesting to
Fig 6. Detection of the protein-protein interaction between cGK andMAPK by co-
immunoprecipitation. JejunumWT tissue lysate was incubated with protein A Sepharose beads coupled
with the p44/42 MAPK antibody. After immunoprecipitation, the protein complexes were visualized by
Western blotting using antibodies directed against cGKIα and cGKII. For the immunoprecipitation (IP), no
antibody (no Ab) was used as a negative control and untreated tissue lysate (1 μg/μL, indicated with input)
was used as an additional control.
doi:10.1371/journal.pone.0126057.g006
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note that the phosphorylation in the jejunum cGKII KO tissue was significantly increased
when compared with the WT and cGKI KO tissues; in these tissues, stimulation with 100 μM
DB-cCMP for 15 min led to a ~14-fold increase in phosphorylation compared to the unstimu-
lated control, whereas in WT jejunum tissue the increase was only ~6-fold. Interestingly, this
Fig 7. Activation of MAPK by cCMP (A) Jejunum tissue lysate (WT) or lung tissue lysate (WT) (S5 Fig)
was treated with 100 μMDB-cCMP for the indicated times (15/30/60 min). A protein kinase A inhibitor (AS
5-24 cAK inhibitor, 10 μM) was added or omitted (as described in the Material and Methods). As control,
untreated (1 μg/μL, indicated with input) and unstimulated tissue lysate (2.5 μg/μL, indicated with ‘us’) was
used. Control samples (‘us’) were treated like DB-cCMP stimulated samples but, instead of DB-cCMP, water
was added. The phosphorylation of MAPK was detected by immunoblotting using a phospho-p44/42 MAPK
antibody (pMAPK). Total MAPK was measured by stripping the membrane and retreating with the respective
antibodies. (B) Densitometry analysis of 4–5 independent experiments (numbers in columns) was performed
to quantitate p44/42 MAPK levels. Data were expressed as x-fold MAPK phosphorylation relative to
untreated control samples. Error bars showmean ± SEM and asterisks indicate statistically significant
differences, ns: not statistically significant.
doi:10.1371/journal.pone.0126057.g007
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effect was not observed in lung tissues. In summary, these results suggest an inhibitory role for
cGKII in cCMP-induced MAPK phosphorylation in the jejunum.
Discussion
In this study, we used cCMP kinase activity assays and affinity chromatography to identify
cGKII and MAPK as possible cCMP effector molecules, and confirmed that cGKI and cAK
function as cCMP interactors. The activation of the kinase activity of the cGKI isoforms in ad-
dition to cGKII and cAK by cCMP using IRAGtide as a substrate is in agreement with previ-
ously published data [26]. Interestingly, although the IRAG protein is a specific substrate for
cGKIβ, cGKIα phosphorylation was more effective compared to cGKIβ when IRAGtide was
used as the substrate. This result indicates that the substrate specificity resulted from an IRAG-
cGKIβ interaction site located outside of the kinase domain [22]. Our observations implied
that cCMP might modulate diverse tissue functions. The confirmation of the presence of
Fig 8. Activation of MAPK by cCMP in (A) cGKII KO tissue or in cGKI KO tissue (both jejunum tissue
lysate). Tissue lysate was stimulated with 100 μMDB-cCMP for the indicated times (15/30/60 min). As
control, untreated (1 μg/μL, indicated with input) and unstimulated tissue lysate (2.5 μg/μL, indicated with ‘us’)
was used. Control samples (‘us’) were treated like DB-cCMP stimulated samples but, instead of DB-cCMP,
water was added. The phosphorylation of MAPK was detected by immunoblotting using a pMAPK antibody.
Total MAPK was measured by stripping the membrane and retreating with the respective antibody. (B)
Densitometry analysis of 3–5 independent experiments (numbers in columns) was performed to quantitate
p44/42 MAPK levels. Data were expressed as x-fold MAPK phosphorylation relative to untreated control
samples. cGKII KO and cGKI KO data were compared with WT data. Error bars showmean ± SEM. Asterisks
indicate statistically significant differences, ns: not statistically significant. The same experiment was
conducted with lung tissue lysates (S7 Fig).
doi:10.1371/journal.pone.0126057.g008
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cCMP and cUMP using HPLC and mass spectrometry suggested that the concentrations of
these cyclic nucleotides in cells strongly varied [1,27]. Thus, the stimulation of cyclic nucleotide
synthesis may diverge in different cells and tissues. Furthermore, effects on different signaling
pathways could be exerted in distinct tissues. For example, HCN channels could be modulated
by cCMP [28]. In this study, we determined that target proteins of cCMP were present in sever-
al tissues, including the lung and jejunum. In addition to the recently established cCMP-
binding proteins cGKI and cAKRI, we identified cGKII and MAPK as possible signaling pro-
teins that interact with cCMP. This finding broadens the functions of cCMP. cCMP acts as a
signaling molecule; therefore, cCMP might alternatively modulate both the cGK and cAK sig-
naling pathways by acting as a non-canonical second messenger. Interestingly, in previous
studies both cCMP and cUMP were detected in the gastric mucosa, indicating a probable func-
tion for these molecules in the gastrointestinal tract [29]. The identification of diverse effectors
of cCMP could lead to the discovery of its possible roles in the signaling pathways of diverse tis-
sues. For example, cGKI is strongly involved in the relaxation processes. Previously, the role of
cCMP via cGKI in vascular relaxation was elucidated using cGKI-knockout mice [7]. Our re-
sults investigating the role of cCMP in intestinal and lung tissues may indicate that relaxation
in these tissues is inter alia regulated by cCMP. The role of cCMP/cGKII in these tissues would
most likely be involved in intestinal secretion or lung alveolar fluid clearance [19,30]. As previ-
ously discussed [9], cCMP/cAKRI regulates a large variety of cellular processes. However, its
role in vivo might be less important than that recently described in an investigation into CREB-
phosphorylation in S49 lymphoma cells [31]. MAPK stimulation of cAK via Ras/Raf has been
demonstrated [32]. Therefore, cCMP may activate MAPK phosphorylation by cAK via a simi-
lar signaling pathway. Our results support this stimulatory effect of cAMP/cAK. However,
other reports have described the inhibition of MAPK phosphorylation by cAMP/cAK via Rap1
[33]. The newly discovered correlation of cCMP/cGK with MAPK could indicate a role in cel-
lular proliferation. However, this is a highly controversial topic because it is unclear whether
cGKI functions in a proliferative or anti-proliferative fashion, and it is not clear how cGKI
modulates the signaling of MAPK. Endogenous cGK has been reported to reverse EGF-induced
MAPK signaling and thereby inhibit cellular proliferation [34,35]. However, these authors re-
ported that the reduced phosphorylation of p44/42 MAPK by cGMP occurred in a manner
that was reversible using a PKG or PKC inhibitor. Additionally, an active role for NO/cGMP/
cGKIα on MAPK phosphatase MKP-1 was previously reported in insulin-treated vascular
smooth muscle cells [36], and another report showed that p42/p44 MAPK was a potential tar-
get of cGKI in pancreatic adenocarcinoma cells, thereby inducing cellular proliferation [25].
There are also divergent results concerning whether MAPK signaling is activated or inhibited
by the cGKII isoform. cGKII was shown to inhibit MAPK signaling induced by growth factors,
and thereby interfere with the cellular proliferation and migration of breast and gastric cancer
cells, respectively [24,37,38]. Our results support a suppressive role for cGKII on MAPK phos-
phorylation and an inhibitory function on this signaling pathway. cGKII is more strongly ex-
pressed in the jejunum than the lung. This finding might explain the reason that this effect was
associated with the jejunum tissue lysates. Regardless, the mechanism of action of cGKII is not
clear and needs to be elucidated in future studies. It might be possible that MAPK phosphatases
are involved or directly targeted by cGKII. However, other reports have suggested that intesti-
nal cell proliferation might be stimulated by guanylyl cyclase via cGKII/MAPK [23]. Here, we
showed that a complex of cGKI/MAPK or cGKII/MAPK may be activated by cCMP. However,
how this complex is formed and whether adaptor proteins are necessary to assemble this kinase
complex is unknown. It would be interesting to discover whether these complexes regulate cel-
lular processes in diverse tissues. Further studies are necessary to elucidate these mechanisms
and to establish the probable cellular functions of cCMP effector proteins.
Interaction of cCMP with cGK, cAK and MAPK
PLOSONE | DOI:10.1371/journal.pone.0126057 May 15, 2015 14 / 18
Supporting Information
S1 Fig. Activation of kinases in tissues of wild type (WT) and cGKI-knockout (KO) mice
using two different substrate peptides: VASPtide (RRKVSKQE) and IRAGtide
(RRRVSVAV). (A/B) Stimulation of endogenous cGKs in lung or jejunum tissue lysates after
activation with water alone (ctrl) or cGMP (50 nM or 5 μM). (C/D) Same panel as (A/B) using
cAMP (500 nM or 100 μM). Data were expressed as x-fold stimulation relative to control sam-
ples (water alone). Error bars indicate mean±SEM of three independent experiments. Asterisks
indicate statistically significant differences, ns: not statistically significant.
(TIF)
S2 Fig. Identification of cCMP-binding proteins (A) Lung tissue lysate (WT) was incubated
with 4-AH-cCMP agarose beads or EtOH-NH-agarose beads (ctrl). For the competition ex-
periments, cCMP (2 mM) was added (+) or omitted (-) as described in the Material and Meth-
ods. Untreated tissue lysate (1 μg/μL, indicated with input) and purified enzyme (1.5 ng/μL)
were used as the controls. Purified enzymes are designated with  (B) Same panel as (A) using
jejunum (WT) lysate. cCMP-binding proteins were analyzed by electrophoresis and immuno-
blotting with antibodies directed against cGKIc, cGKII or cAKRIα/β (C) JejunumWT tissue ly-
sate was incubated with 4-AH-cCMP agarose beads or EtOH-NH-agarose beads (ctrl). For the
competition experiments, cAMP (2 mM) was added (+) or omitted (-). Untreated tissue lysate
(1 μg/μL, indicated with input) was used as control; bound proteins were analyzed by electro-
phoresis and immunoblotting (cGKIc antibody).
(TIF)
S3 Fig. Identification of cCMP-binding proteins (A) Lung tissue lysate (WT, cGKI KO and
cGKII KO) was incubated with 4-AH-cCMP agarose beads or EtOH-NH-agarose beads
(ctrl). For the competition experiments, cCMP (2 mM) was added (+) or omitted (-) as de-
scribed in the Material and Methods. Untreated tissue lysate (1 μg/μL, indicated with input)
was used as an additional control. cCMP-binding proteins were analyzed by electrophoresis
and immunoblotting with an antibody directed against p44/42 MAPK (B) Same panel as (A)
using jejunum tissue lysate (WT, cGKI KO and cGKII KO).
(TIF)
S4 Fig. Identification of cGMP-binding proteins. Lung and jejunumWT tissue lysates were
incubated with 8-AET-cGMP agarose beads or EtOH-NH-agarose beads (ctrl). For the compe-
tition experiments, cGMP (200 μM) was added (+) or omitted (-) as described in the Material
and Methods. Untreated tissue lysate (1 μg/μL, indicated with input) was used as an additional
control. cGMP-binding proteins were analyzed by electrophoresis and immunoblotting with
antibodies directed against cGKIc, cGKII or p44/42 MAPK.
(TIF)
S5 Fig. Activation of MAPK by cCMP. Lung tissue lysate (WT) was treated with 100 μMDB-
cCMP for the indicated times (15/30/60 min). A protein kinase A inhibitor (AS 5-24 cAK inhib-
itor, 10 μM) was added or omitted (as described in the Material and Methods). The phosphory-
lation of MAPK was detected by immunoblotting using a phospho-p44/42 MAPK antibody
(pMAPK). Total MAPK was measured by stripping the membrane and retreating with the re-
spective antibodies. Densitometry analysis of 4–6 independent experiments (numbers in col-
umns) was performed to quantitate the p44/42 MAPK levels. Data were expressed as x-fold
MAPK phosphorylation relative to untreated control samples. Error bars show mean ± SEM.
Asterisks indicate statistically significant differences, ns: not statistically significant.
(TIF)
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S6 Fig. Activation of MAPK by cCMP.WT tissue lysates (lung or jejunum) were treated with
100 μMDB-cCMP for the indicated times (15/30/60 min). The phosphorylation of MAPK was
detected by immunoblotting using a phospho-p44/42 MAPK antibody (pMAPK). Total
MAPK was measured by stripping the membrane and retreating with the respective antibodies.
Densitometry analysis of 5–6 independent experiments (numbers in columns) was performed
to quantitate pMAPK levels. Data were expressed as x-fold MAPK phosphorylation relative to
untreated control samples. Error bars show mean ± SEM. Asterisks indicate statistically signifi-
cant differences, ns: not statistically significant.
(TIF)
S7 Fig. Activation of MAPK by cCMP in cGKII KO tissue or in cGKI KO tissue (both lung
tissue lysate). Tissue lysate was stimulated with 100 μMDB-cCMP for the indicated times (15/
30/60 min). As control, untreated (1 μg/μL, indicated with input) and unstimulated tissue ly-
sate (2.5 μg/μL, indicated with ‘us’) was used. Control samples (‘us’) were treated like DB-
cCMP stimulated samples but, instead of DB-cCMP, water was added. The phosphorylation of
MAPK was detected by immunoblotting using pMAPK antibody. Total MAPK was measured
by stripping the membrane and retreating with the respective antibody. Densitometry analysis
of 3–6 independent experiments (numbers in columns) was performed to quantitate p44/42
MAPK levels. Data were expressed as x-fold MAPK phosphorylation relative to untreated con-
trol samples. cGKII KO and cGKI KO data were compared with WT data. Error bars show
mean ± SEM. Asterisks indicate statistically significant differences, ns: not
statistically significant.
(TIF)
S1 Table. Identification of cCMP-binding proteins in lung WT tissue lysate via cCMP aga-
rose precipitation, gel electrophoresis, silver staining (Fig 3) and mass spectrometric analy-
sis. Bands of interest were excised from the silver stained gel and handled as described in
Material and Methods. The analysis was carried out using a nano-LC-MS/MS system and the
tandemMS-spectra were aligned with the Uniprot-database.
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